ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma — ABC-lung  

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Clinical Trial

Official title: A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance

Status Active, not recruiting

Clinical Trial Summary

ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
• Lung Neoplasms

• NCT number: NCT04245085
• Study type: Interventional
• Source: ETOP IBCSG Partners Foundation
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 29, 2020
• Completion date: December 2024